Drug Update · Rare Disease

FDA Approves lunsotogene parvec (OTARMENI) for OTOF-Related Hearing Loss: 80% Achieved PTA ≤70 dB HL

September 09, 2026

FDA approval date

April 23, 2026

Indication

Severe-to-profound and profound SNHL (any frequency >90 dB HL) with molecularly confirmed biallelic OTOF variants, preserved outer hair cell function, no prior cochlear implant in the treated ear

Primary efficacy

16 of 20 evaluable patients (80%) achieved average PTA ≤70 dB HL at Week 24 in Study DB-OTO-001 [6]

Recommended dose

7.2 × 10 12 vector genomes (vg) in 0.24 mL per ear, single-dose intracochlear infusion [6]

Key safety events

Middle ear infection, nausea, dizziness, procedural pain, meningitis risk noted in label/press materials [2][6]

Clinical Perspective

This approval affects otolaryngologists, pediatric audiologists, geneticists, and clinicians who evaluate and manage patients with genetically confirmed OTOF-associated severe-to-profound or profound sensorineural hearing loss. The accelerated approval supports use of OTARMENI in patients meeting the exact molecular and audiologic eligibility (molecularly confirmed biallelic OTOF variants, preserved outer hair cell function, no prior cochlear implant in the same ear) based on improvements in PTA at Week 24 ^[4]^[5]. Key unanswered clinical questions include how durable treatment effects will be in larger, longer-term cohorts and how functional speech and language outcomes evolve over time following administration?

Dr. Lakshmi Venkatesan, MBBS, MD (Paediatrics), DM (Medical Genetics) · Medical Genetics

Lunsotogene parvec-cwha (OTARMENI) was approved by the FDA on April 23, 2026 for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear ^[4]^[5]. Approval was granted under accelerated approval; in a single-arm, multicenter study (Study DB-OTO-001), 16 of 20 evaluable patients (80%) achieved the primary endpoint of an average pure tone audiometry (PTA) threshold ≤70 dB HL at Week 24 ^[5].

Clinical Context

Lunsotogene parvec is a dual adeno-associated virus (AAV) vector-based gene transfer therapy developed by Regeneron Pharmaceuticals that delivers an OTOF transgene to inner hair cells to facilitate production of functional otoferlin protein and restore synaptic transmission to the auditory nerve, as described in regulatory and peer-reviewed summaries ^[1]^[2]^[5]. The product is supplied with an Administration Kit and is intended for intracochlear infusion only; it is indicated for patients with molecularly confirmed biallelic OTOF variants and preserved outer hair cell function who have not previously received a cochlear implant in the treated ear ^[4]^[5]. The approval follows a rapid review under the Commissioner’s National Priority Voucher pilot and was issued 61 days after BLA filing, with accelerated approval status and postmarketing commitments to verify clinical benefit ^[2]^[4].

Key Findings

Study DB-OTO-001, an ongoing multi-center, single-arm study, reported that 16 of 20 evaluable patients (80%) achieved the primary efficacy endpoint of an average PTA threshold ≤70 dB HL at Week 24 after intracochlear administration of OTARMENI ^[5].
The key secondary endpoint—presence of an auditory brainstem response (ABR) to a click stimulus of ≤90 dB nHL at Week 24—was achieved by 14 of 20 evaluable patients (70%) ^[5].
At Week 24, 9 of 20 patients (45%) achieved an average PTA threshold ≤45 dB HL and 3 of 20 patients (15%) achieved ≤25 dB HL; by Week 48, among 12 patients with Week 48 data, 10 of 12 (83%) achieved an average PTA threshold ≤70 dB HL and all 9 patients with an earlier response maintained response at Week 48 ^[5].
The pivotal dataset in the prescribing information reflects treatment in 24 patients who received OTARMENI (10 unilateral, 14 bilateral), with 20 patients completing Week 24 efficacy assessments; NCT05788536 is associated with the clinical development program ^[5]^[4].

Safety & Tolerability

Common adverse events explicitly named in the available sources included middle ear infection, nausea, dizziness, and procedural pain ^[2]. The FDA press announcement additionally instructed providers to monitor for surgical complications as part of post-procedure care ^[2]. The prescribing information notes that clinicians should vaccinate against organisms that cause meningitis before surgery because meningitis is a known risk of inner ear surgery and advises vaccination timing relative to corticosteroid use ^[5]. No other adverse events beyond those explicitly named in the provided source excerpts were reported here. SAFETY BULLET COUNT: 5

Study Design

The efficacy data supporting the accelerated approval derive principally from Study DB-OTO-001, an ongoing, multi-center, single-arm study that enrolled pediatric patients with molecularly confirmed OTOF-associated profound sensorineural hearing loss; the study and its results are described in the approved prescribing information and FDA reviews ^[5]^[3]. The BLA (STN BLA 125874/0) was received December 23, 2025, recommended for approval by the reviewing committee and granted accelerated approval by FDA on April 23, 2026; the application was tied to NCT05788536 in the approval letter ^[3]^[4]. Continued approval may be contingent on verification of clinical benefit in a confirmatory study and postmarketing observational safety follow-up commitments, including a prospective observational study to characterize long-term safety in a minimum of 50 patients with 10-year follow-up ^[4].

FAQ

Q1 What is lunsotogene parvec (OTARMENI) approved for?

OTARMENI (lunsotogene parvec-cwha) is approved for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, provided they have preserved outer hair cell function and no prior cochlear implant in the same ear. The approval was granted under accelerated approval based on improvement in pure tone audiometry at Week 24.

Q2 How does lunsotogene parvec work?

Intracochlear infusion of OTARMENI results in expression of the OTOF transgene primarily in inner hair cells, which facilitates production of functional otoferlin protein and restores synaptic transmission to the auditory nerve, as demonstrated in preclinical and clinical program materials. The product is delivered via a dual AAV vector platform designed to accommodate the OTOF coding sequence and target inner hair cell expression.

Q3 What is the recommended dose of OTARMENI?

The recommended dose for each ear is 7.2 × 10 12 vector genomes (vg) in a total volume of 0.24 mL, administered by a single-dose intracochlear infusion. Administration should be performed by a surgeon experienced in intracochlear surgery and trained in the procedure. Per the label, systemic oral corticosteroids equivalent to prednisone 1 mg/kg/day should be given the day of infusion, maintained for two weeks, then tapered over two weeks, with a total corticosteroid dose not to exceed 60 mg/day; age-appropriate vaccinations should be given outside the corticosteroid window per label guidance. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects of OTARMENI?

Reported common adverse events in the approval materials included middle ear infection, nausea, dizziness, and procedural pain; providers were advised to monitor for surgical complications. The label also highlights meningitis as a known risk of inner ear surgery and recommends appropriate vaccination timing relative to immunosuppression for prophylaxis. Full safety information and contraindications are detailed in the prescribing information.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves lunsotogene parvec (OTARMENI) for OTOF-Related Hearing Loss: 80% Achieved PTA ≤70 dB HL

Direct Clinical Takeaway & Evidence Summary

FDA Approves lunsotogene parvec (OTARMENI) for OTOF-Related Hearing Loss: 80% Achieved PTA ≤70 dB HL

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Cite & Reference This Monograph

Get weekly clinical updates for Rare Disease in your inbox.

Related Clinical Updates

FDA Approves Zycubo for Menkes Disease: Cuts Death Risk 78%

Lunsotogene parvec (Otarmeni) FDA Approves for OTOF-Associated Hearing Loss: 80% Hearing Response

navepegritide (Yuviwel) FDA Approves for Achondroplasia: 1.5 cm/yr AGV Gain

Verified HCP Portal